The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved the use of Moderna’s covid-19 vaccine Spikevax on children aged 12-17, according to an EMA press release.
The committee has approved the vaccine following studies involving 3,732 children in this age group, which showed that its efficacy and side effects much resembled those seen in adults who have received the vaccine.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.